FT. LEE, N.J.--(EON: Enhanced Online News)--SAFE-BioPharma Association, the non-profit collaboration that developed and manages the global SAFE-BioPharma® digital identity and digital signature standard, has elected Greg Koski, PhD, MD to its Board of Directors. Dr. Koski is Co-Founder & President/CEO, Alliance for Clinical Research Excellence and Safety (ACRES), Boston, MA. ACRES is a private, non-profit global network for clinical research based on standardized policies and procedures, regulatory simplification, professionalism and information technology.
“Greg Koski is a well-regarded leader at the intersection of clinical research and technology. He will provide valuable guidance for advancing use of the SAFE-BioPharma digital identity and digital signature standard in the broader research community”
The SAFE-BioPharma standard is a strategic initiative of the life sciences industry to facilitate secure, trusted and fully electronic business and regulatory processes. The standard is used throughout the biopharmaceutical and healthcare industries to manage digital identity trust and to apply legally binding digital signatures to electronic documents. The association’s members include most of the world’s largest biopharmaceutical companies.
SAFE-BioPharma's all-volunteer Board sets strategic direction, determines the business model, and oversees the association's management. Recent initiatives include global expansion of the standard through integration with biopharmaceutical and healthcare industry applications such as signing engines, portal providers, clinical trial applications, ePrescribing, access to eHRs, and other critical digital workflows.
In addition to his role with ACRES, Dr. Koski is Senior Scientist, James Mongan Institute for Health Policy and Associate Professor of Anesthesia, Massachusetts General Hospital, Harvard Medical School. He earned his MD, PhD and AB degrees from Harvard University.
"Greg Koski is a well-regarded leader at the intersection of clinical research and technology. He will provide valuable guidance for advancing use of the SAFE-BioPharma digital identity and digital signature standard in the broader research community," said Mollie Shields-Uehling, president and CEO and a director of SAFE-BioPharma Association.
For more information on the SAFE-BioPharma standard for digital identity and digital signatures used in life science and healthcare settings, visit http://www.safe-biopharma.org.
SAFE-BioPharma® is a trademark of SAFE-BioPharma Association. Any use of this trademark requires approval from SAFE-BioPharma Association.